Floatz logo

Rqnestin

Mixed Oligo-Astrocytoma

Dana-Farber Cancer InstitutePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Mixed Oligo-Astrocytoma cohort.

Asset / SponsorPhaseRating
Cintredekin Besudotox
INSYS Therapeutics Inc
Phase 1/2BB
CHLOROTOXIN
TransMolecular
Phase 2CCC
ETOPOSIDE
Washington University School of Medicine
Phase 2CCC
Inno-206
Washington University School of Medicine
Phase 2CCC
GBM6-AD
Jennie Taylor
Phase 1CC

View all 12 →

Same molecule, other indications

Rqnestin is also rated in:

astrocytic tumorDormant
CC
Indicative ·
43 / 100
View asset →
anaplastic astrocytomaDormant
CC
Indicative ·
43 / 100
View asset →
brain gliomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →